There have been 29 cases of acute non-viral hepatitis with an unknown cause identified in the state. The Hawaii DOH has reported that 24 of these cases share a common link to OxyElite Pro. Eleven of the 29 cases have been hospitalized with acute hepatitis, two cases have received liver transplants and one person has died. CDC is also looking at other cases of liver injury nationwide that may be related.
The FDA advises consumers to stop using any dietary supplement products labeled as OxyElite Pro while the investigation continues. OxyElite Pro is distributed by USPlabs LLC of Dallas, TX, and is sold nationwide through a wide range of distribution channels, including the Internet and retail stores that sell dietary supplements. USPlabs LLC has informed the FDA that it will voluntarily cease distributing OxyElite Pro as the company cooperates with the investigation.
The epidemiological investigation is being conducted by the Hawaii DOH and the CDC. As part of FDA’s associated investigation, the agency is reviewing the medical records and histories of patients identified by the Hawaii DOH. The FDA is also analyzing the composition of product samples that have been collected from some of these patients. Additionally, the FDA is inspecting the facilities involved in manufacturing the product and reviewing production and product distribution records. Because USPlabs LLC has informed FDA that it believes counterfeit versions of OxyElite Pro are being marketed in the U.S. and have been on the U.S. market for some time, FDA is also investigating whether counterfeit product is related to any of the cases of acute hepatitis.